# Sail Biomedicines

Sail Biomedicines is an Asset Manager based in United States, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** United States, United States
- **Region:** North America
- **Address:** United States
- **Founded:** 2023
- **Assets under management:** Undisclosed
- **Website:** sail.bio
- **LinkedIn:** https://www.linkedin.com/company/sail-biomedicines

## Regulatory record

- **Reports private funds:** No

## About

A Flagship Pioneering Company Our scientists created a platform to unlock the therapeutic power of eRNA & TNPs Sail has..

## Sectors

- Biotech
- Healthcare Services

## People

- John Mendlein — Executive Chairman
- Gene Marcantonio — Chief Medical Officer
- Ewen Cameron — SVP, Platform
- Amy Espeseth — Head of Pharmacology and Vaccines
- Vincent Hennemand — Chief Product & Operations Officer
- Rafal Kowalczyk — Head of Finance
- Michael Mingueneau — SVP, Head of Immunology
- Jim Nolan — SVP, Head of Technical Development & Operations
- Mark Umbarger — Head of Artificial Intelligence & Digital Sciences
- Michael Lam — Vice President, Strategy & Scientific External Affairs

## Questions

### Who leads investment decisions at Sail Biomedicines?

John Mendlein serves as Executive Chairman and is the most senior executive, with a background at Moderna and Flagship Pioneering. The board includes Flagship partners and independent directors such as Pablo Cagnoni (Incyte) and Frank D'Amelio (former Pfizer CFO). Investment decisions around platform development and pipeline prioritization are made by the leadership team and board, per the firm's website.

### How does Sail Biomedicines source its technology?

Sail was formed by Flagship Pioneering, consolidating technologies developed across its ecosystem, including eRNA from Laronde (a Flagship company) and targeted nanoparticle work from other portfolio firms. The platform integrates these assets with proprietary AI for medicine design.

### What investment stages does Sail Biomedicines target?

Sail is a preclinical-stage biotech platform company. It is building a pipeline of candidate medicines for autoimmune, metabolic, infectious, and rare diseases, with an initial focus on advancing an in vivo CAR-T program toward clinical trials.

### How is Sail Biomedicines related to Flagship Pioneering?

Sail is a Flagship Pioneering company, meaning it was conceived and built within Flagship's venture creation engine. Flagship provides strategic, operational, and financial support, and several Flagship executives and partners sit on Sail's board.

## Related profiles

- [National Institute of Mental Health](https://altss.com/profile/national-institute-of-mental-health)
- [Home Care Pulse](https://altss.com/profile/home-care-pulse)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/sail-biomedicines

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology